Mustang Bio, Inc. (NASDAQ:MBIO) Sees Large Growth in Short Interest

Mustang Bio, Inc. (NASDAQ:MBIO) was the recipient of a significant growth in short interest in February. As of February 13th, there was short interest totaling 220,214 shares, a growth of 405.2% from the January 29th total of 43,589 shares. Based on an average daily volume of 771,653 shares, the days-to-cover ratio is currently 0.3 days. Approximately 3.1% of the shares of the stock are sold short. Approximately 3.1% of the shares of the stock are sold short. Based on an average daily volume of 771,653 shares, the days-to-cover ratio is currently 0.3 days.

Mustang Bio Trading Up 2.0%

Shares of Mustang Bio stock opened at $1.03 on Thursday. The firm has a market cap of $7.52 million, a PE ratio of -3.32 and a beta of 2.14. The stock has a 50 day moving average of $0.99 and a 200 day moving average of $1.29. Mustang Bio has a 12 month low of $0.53 and a 12 month high of $7.00.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mustang Bio in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On Mustang Bio

A hedge fund recently raised its stake in Mustang Bio stock. Kestra Advisory Services LLC grew its holdings in shares of Mustang Bio, Inc. (NASDAQ:MBIO) by 68.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 111,042 shares of the company’s stock after buying an additional 44,934 shares during the quarter. Kestra Advisory Services LLC owned 1.52% of Mustang Bio worth $109,000 at the end of the most recent reporting period. 9.95% of the stock is currently owned by institutional investors.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.